WALTHAM, Mass.--(BUSINESS WIRE)--Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced that it will present initial dose escalation results from its Phase 1 KisMET-01 study evaluating its investigational cMET-targeting ADC, MYTX-011, in patients with previously treated, locally advanced or metastatic non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Annual Meeting..

马萨诸塞州沃尔瑟姆（商业新闻短讯）--Mythic Therapeutics是一家致力于开发用于治疗多种癌症的下一代抗体-药物偶联物（ADC）疗法的临床阶段生物技术公司，今天宣布，它将在美国临床肿瘤学会（ASCO）年会上展示其第一阶段KisMET-01研究的初始剂量递增结果，该研究评估了其针对先前治疗的局部晚期或转移性非小细胞肺癌（NSCLC）患者的研究性cMET靶向ADC MYTX-011。。

“We are pleased to present clinical data showcasing the potential of our lead program, MYTX-011, for patients impacted by non-small cell lung cancer,” said Gilles Gallant, BPharm, Ph.D., FOPQ, Chief Development Officer at Mythic Therapeutics. “The initial dose escalation results from our ongoing KisMET-01 trial mark an important milestone in our journey, and we look forward to sharing these results with the scientific community at ASCO.”.

Mythic Therapeutics首席开发官、BPharm博士Gilles Gallant说：“我们很高兴提供临床数据，展示我们的领先项目MYTX-011对非小细胞肺癌患者的潜力。”。“我们正在进行的KisMET-01试验的初始剂量递增结果标志着我们旅程中的一个重要里程碑，我们期待着与ASCO的科学界分享这些结果。”。

Details of the presentation are as follows:

演示的详细信息如下：

Title: MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.

标题：先前接受过局部晚期或转移性NSCLC治疗的患者的MYTX-011：KisMET-01研究的初始剂量递增结果。

Presenter: Melissa Johnson, M.D., Director, Lung Cancer Research, Sarah Cannon Research Institute

主持人：梅丽莎·约翰逊医学博士，莎拉·坎农研究所肺癌研究主任

Session Title: Lung Cancer—Non-Small Cell Metastatic

会议标题：肺癌非小细胞转移

Session Date and Time: Monday, June 3, 1:30 - 4:30 PM CDT

会议日期和时间：6月3日星期一下午1:30-4:30 CDT

Location: Hall A | On Demand

地点：A厅|按需

Poster Board Number: 422

海报板编号：422

Published Abstract Number: 8558

出版摘要编号：8558

About MYTX-011

关于MYTX-011

MYTX-011, an investigational cMET-targeting ADC, leverages Mythic’s innovative FateControl™ technology which is designed to allow ADCs to actively navigate inside of cells, potentially increasing delivery of anti-cancer agents to tumor cells with less impact on healthy cells. This breakthrough approach takes the next step beyond linker-payload technologies and is designed to improve ADC efficacy against a broad set of molecular targets and patient profiles.

MYTX-011是一种针对ADC的研究性cMET，利用Mythic的创新FateControl™技术，该技术旨在使ADC在细胞内主动导航，从而有可能增加抗癌药物向肿瘤细胞的递送，而对健康细胞的影响较小。这种突破性的方法超越了连接器有效载荷技术，旨在提高ADC对广泛分子靶标和患者概况的疗效。

MYTX-011 is currently being evaluated in the Phase 1 KisMET-01 clinical trial, a first-in-human, open-label, multi-center, dose escalation and dose expansion study enrolling patients with locally advanced, recurrent or metastatic NSCLC (NCT05652868)..

MYTX-011目前正在1期KisMET-01临床试验中进行评估，该试验是首次针对局部晚期，复发或转移性NSCLC患者的人体，开放标签，多中心，剂量递增和剂量扩展研究（NCT05652868）。。

About Mythic Therapeutics

关于神话疗法

Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The Company’s FateControl™ technology aims to enhance ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the diseases and patient profiles that could be treated with Mythic’s ADCs.

Mythic Therapeutics是一家产品平台公司，开发了一系列抗体-药物偶联物（ADC），旨在展示无与伦比的治疗指数和疗效。该公司的FateControl™技术旨在通过操纵细胞内ADC的命运来增强靶组织中ADC的摄取，从而扩大可以用Mythic的ADC治疗的疾病和患者概况。

The company’s major investors include Venrock, Viking Global Investors, and First Round Capital..

该公司的主要投资者包括Venrock、Viking Global investors和First Round Capital。。

For more information, visit: www.mythictx.com and follow on LinkedIn.

有关更多信息，请访问：www.mythictx.com并关注LinkedIn。